Fusobacterium nucleatum enhances the efficacy of PD-L1 blockade in colorectal cancer
Abstract Given that only a subset of patients with colorectal cancer (CRC) benefit from immune checkpoint therapy, efforts are ongoing to identify markers that predict immunotherapeutic response. Increasing evidence suggests that microbes influence the efficacy of cancer therapies. Fusobacterium nuc...
Guardado en:
Autores principales: | Yaohui Gao, Dexi Bi, Ruting Xie, Man Li, Jing Guo, Hu Liu, Xianling Guo, Juemin Fang, Tingting Ding, Huiyuan Zhu, Yuan Cao, Meichun Xing, Jiayi Zheng, Qing Xu, Qian Xu, Qing Wei, Huanlong Qin |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Publishing Group
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/590c41649479464395ada50dedae6436 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Aspirin Modulation of the Colorectal Cancer-Associated Microbe Fusobacterium nucleatum
por: Caitlin A. Brennan, et al.
Publicado: (2021) -
The role of Fusobacterium nucleatum in colorectal cancer: from carcinogenesis to clinical management
por: Chun-Hui Sun, et al.
Publicado: (2019) -
Diagnostic accuracy of Fusobacterium nucleatum IgA and IgG ELISA test in colorectal cancer
por: Melike Kurt, et al.
Publicado: (2021) -
Infección pulmonar y torácica por Fusobacterium nucleatum
por: Hoffmeister B.,Claudio, et al.
Publicado: (2021) -
Fusobacterium nucleatum and oral cancer: a critical review
por: Emily McIlvanna, et al.
Publicado: (2021)